Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform
November 4, 2015 9:30 AM ESTLeerink Partners maintained a Market Perform rating and $12.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), following the company's 3Q earnings report. IRWD reported 3Q Linzess sales of ~$117m coming in modestly below Leerink's estimate of ~$121m.
Analyst Jason Gerberry commented, "IRWD reported 3Q Linzess sales of ~$117m coming in modestly... More
Leerink Affirms Ironwood Pharma (IRWD) at 'Market Perform'; No Catalyst Seen in Next 12 - 18 Months
November 4, 2015 9:09 AM ESTLeerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday night.
Analyst Jason Gerberry commented, IRWD reported 3Q Linzess sales of ~$117 million coming in modestly below our est. of ~$121 million. The miss was modest, and we dont... More
Ironwood Pharma (IRWD) Misses Q3 EPS by 5c
November 3, 2015 4:23 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.25), $0.05 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $39.6 million versus the consensus estimate of $41.76 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More